Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06906380 · ClinicalTrials.gov registry record
A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies
A clinical trial, sponsored by ARCE Therapeutics.
- Not yet
- Registry status
- 49
- Enrollment target
NCT06906380: Clinical Trial study, sponsored by ARCE Therapeutics.
NCT06906380 is a clinical trial that has not yet begun recruiting, run by ARCE Therapeutics. The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06906380 has not yet begun recruiting, sponsored by ARCE Therapeutics.
- NOT YET RECRUITING
- Registry status
- 49 participants
- Enrollment target
Study Summary
This study will evaluate the long-term safety of ARD103 cellular therapies
Primary Outcome
The number and percentages of participants experiencing TEAEs will be tabulated. Serious TEAEs will be summarized and AESIs will be summarized.
Interventions
- OTHER Non interventional study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2026-03-15 |
| Est. Completion | 2040-10-31 |
What is known before NCT06906380 opens enrollment
NCT06906380 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 49 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Non interventional study is the first listed.
NCT06906380 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06906380 about?
NCT06906380 is a clinical study titled "A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies". This study will evaluate the long-term safety of ARD103 cellular therapies
What is the current status of trial NCT06906380?
This trial is currently not yet recruiting. The enrollment target is 49 participants. The study started on 2026-03-15. Estimated completion is 2040-10-31.
What interventions are being tested in trial NCT06906380?
The interventions under investigation include: Non interventional study (OTHER).
Who is sponsoring clinical trial NCT06906380?
This trial is sponsored by ARCE Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI